DAVID G MENTER to Sulfonamides
This is a "connection" page, showing publications DAVID G MENTER has written about Sulfonamides.
Connection Strength
0.108
-
Reduced 15S-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, NS398. Neoplasia. 2003 Mar-Apr; 5(2):121-7.
Score: 0.028
-
Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors. Invest New Drugs. 2023 02; 41(1):25-34.
Score: 0.027
-
Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. Gastroenterology. 2021 07; 161(1):196-210.
Score: 0.024
-
Effect of cyclooxygenase inhibitors in the adhesion of tumor cells to endothelial cells. Crit Rev Biomed Eng. 2000; 28(1-2):193-4.
Score: 0.022
-
Formation and antiproliferative effect of prostaglandin E(3) from eicosapentaenoic acid in human lung cancer cells. J Lipid Res. 2004 Jun; 45(6):1030-9.
Score: 0.007